Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAUL R MENA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1609892256
CMS profile
118905
Location
BURBANK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$62.94

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $39.02 4
Education $23.92 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $21.49 3
Kite Pharma, Inc. $17.20 1
Seagen Inc. $12.33 1
Gilead Sciences, Inc. $11.92 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAUL R MENA

NPI 1609892256 · CMS profile ID 118905

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BURBANK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609892256?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAUL R MENA, NPI 1609892256, CMS profile ID 118905. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609892256?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RAUL R MENA, NPI 1609892256, CMS profile ID 118905. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609892256?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RAUL R MENA, NPI 1609892256, CMS profile ID 118905, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1609892256?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $62.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $3.7911/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948959089 CMS
PFIZER INC. $5.7010/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948958865 CMS
Seagen Inc. $12.3308/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832161941 CMS
PFIZER INC. $12.0008/11/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832938721 CMS
Kite Pharma, Inc. $17.2006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844418149 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845876527 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $165.85 10
PY2021 $62.94 6
PY2022 $44.07 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $175.09 1
PY2024 Principal investigator $3,280.00 3
PY2023 Principal investigator $10,185.60 2
PY2022 Recipient $6,880.00 1
PY2022 Principal investigator $325,752.17 18
PY2021 Recipient $18.75 1
PY2021 Principal investigator $395,903.61 24
PY2020 Recipient $1,784.80 2
PY2020 Principal investigator $859,478.43 105
PY2019 Recipient $4,319.40 2
PY2019 Principal investigator $2,023,210.35 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

107 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $13,956.30 12/10/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 734923759
Principal investigator 1 Merck Sharp & Dohme Corporation $13.44 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798695
Principal investigator 1 Merck Sharp & Dohme Corporation $176.16 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798697
Principal investigator 1 Merck Sharp & Dohme Corporation $188.64 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798699
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798869
Principal investigator 1 Merck Sharp & Dohme Corporation $30.08 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798871
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798875
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740799051
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740799053
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740799057
Principal investigator 1 Merck Sharp & Dohme Corporation $17.70 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740799211
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 12/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740799213
Principal investigator 1 Genentech, Inc. $7,553.60 12/03/2020 Non-covered Recipient Entity
PROVIDENCE TARZANA MEDICAL CENTER
PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC No dispute reported 06/30/2026 743112261
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $370.50 11/19/2020 Non-covered Recipient Entity
Providence Health System Southern Ca
PCYC-1145-LT No dispute reported 06/30/2026 727738725
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 11/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798873
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 11/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798877
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 11/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798879
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 11/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740799047
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 11/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740799049
Principal investigator 1 Merck Sharp & Dohme Corporation $39,083.94 11/06/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740799055
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 11/06/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer No dispute reported 06/30/2026 740813887
Principal investigator 1 Merck Sharp & Dohme Corporation $39,083.94 11/06/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 740813889
Principal investigator 1 Seagen Inc. $2,687.50 10/23/2020 Non-covered Recipient Entity
PROVIDENCE ST JOSEPH MEDICAL CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733454285
Principal investigator 1 Merck Sharp & Dohme Corporation $1,207.68 09/25/2020 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER, DISNEY FAMILY CANCER
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab LYNK-003. No dispute reported 06/30/2026 740777423
Principal investigator 1 Merck Sharp & Dohme Corporation $475.30 09/25/2020 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER, DISNEY FAMILY CANCER
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab LYNK-003. No dispute reported 06/30/2026 740777425
Principal investigator 1 Merck Sharp & Dohme Corporation $590.70 09/24/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 740813709
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $9,750.00 09/22/2020 Non-covered Recipient Entity
Roy And Patricia Disney Family Cancer Center
PCYC-1141-CA No dispute reported 06/30/2026 727736159
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $1,560.00 09/22/2020 Non-covered Recipient Entity
Roy And Patricia Disney Family Cancer Center
PCYC-1141-CA No dispute reported 06/30/2026 727736347
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $4,973.00 09/22/2020 Non-covered Recipient Entity
Roy And Patricia Disney Family Cancer Center
PCYC-1141-CA No dispute reported 06/30/2026 727736351
Principal investigator 1 Merck Sharp & Dohme Corporation $5,551.25 09/09/2020 Non-covered Recipient Entity
UNAVAILABLE
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 740741951
Principal investigator 1 Merck Sharp & Dohme Corporation $6,505.00 09/09/2020 Non-covered Recipient Entity
UNAVAILABLE
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 740741953
Principal investigator 1 GlaxoSmithKline, LLC. $6,202.80 09/08/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 734924099
Principal investigator 1 Merck Sharp & Dohme Corporation $27,650.00 09/01/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740794083
Principal investigator 1 GlaxoSmithKline, LLC. $99,458.11 08/27/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 734924219
Principal investigator 1 GlaxoSmithKline, LLC. $26,294.40 08/27/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 734925263
Principal investigator 1 GlaxoSmithKline, LLC. $2,868.00 08/25/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 734925755
Principal investigator 1 GlaxoSmithKline, LLC. $11,794.40 08/25/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 734927683
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $185.25 08/20/2020 Non-covered Recipient Entity
Providence Health System Southern Ca
PCYC-1145-LT No dispute reported 06/30/2026 727734295
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $370.50 08/20/2020 Non-covered Recipient Entity
Providence Health System Southern Ca
PCYC-1145-LT No dispute reported 06/30/2026 727734299
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $370.50 08/20/2020 Non-covered Recipient Entity
Providence Health System Southern Ca
PCYC-1145-LT No dispute reported 06/30/2026 727735985
Principal investigator 1 Merck Sharp & Dohme Corporation $39,083.94 08/03/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798693
Principal investigator 1 PFIZER INC. $2,000.00 07/29/2020 Non-covered Recipient Entity
Providence Health Services Southern California Disney Family Cancer Center
POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY No dispute reported 06/30/2026 742949921
Recipient Eli Lilly and Company $475.00 07/21/2020 Covered Recipient Physician A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728723487
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 06/30/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798691
Principal investigator 1 Merck Sharp & Dohme Corporation $1,061.90 06/22/2020 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER, DISNEY FAMILY CANCER
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab LYNK-003. No dispute reported 06/30/2026 740777421
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 06/10/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer No dispute reported 06/30/2026 740813715
Principal investigator 1 Merck Sharp & Dohme Corporation $240.00 06/01/2020 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER, DISNEY FAMILY CANCER
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab LYNK-003. No dispute reported 06/30/2026 740777419
Principal investigator 1 Seagen Inc. $187.50 05/28/2020 Non-covered Recipient Entity
PROVIDENCE ST JOSEPH MEDICAL CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733454183
Principal investigator 1 PFIZER INC. $7,750.00 05/16/2020 Non-covered Recipient Entity
Providence Health Services Southern California Disney Family Cancer Center
POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY No dispute reported 06/30/2026 742968355
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 05/11/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer No dispute reported 06/30/2026 740813713
Principal investigator 1 Merck Sharp & Dohme Corporation $188.64 05/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798689
Principal investigator 1 Merck Sharp & Dohme Corporation $13.44 05/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801975
Principal investigator 1 Merck Sharp & Dohme Corporation $17.70 05/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801977
Principal investigator 1 Merck Sharp & Dohme Corporation $176.16 05/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801979
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 05/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801981
Principal investigator 1 Merck Sharp & Dohme Corporation $30.08 05/08/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801983
Principal investigator 1 GlaxoSmithKline, LLC. $217,932.80 05/05/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 734923867
Principal investigator 1 GlaxoSmithKline, LLC. $115,161.30 05/05/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 734927767
Principal investigator 1 Merck Sharp & Dohme Corporation $39,083.94 04/27/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 740813711
Principal investigator 1 Incyte Corporation $252.00 04/22/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFO
Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome Myeloproliferative Neoplasm No dispute reported 06/30/2026 744283331
Principal investigator 1 Merck Sharp & Dohme Corporation $133.42 03/26/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 740813717
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 03/26/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 740813719
Principal investigator 1 Eli Lilly and Company $9,755.00 03/03/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728747193
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $18,013.50 02/14/2020 Non-covered Recipient Entity
Providence Health System Southern Ca
PCYC-1145-LT No dispute reported 06/30/2026 727725295
Principal investigator 1 Merck Sharp & Dohme Corporation $14.10 02/10/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800271
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 02/10/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800589
Principal investigator 1 Merck Sharp & Dohme Corporation $23.55 02/10/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800933
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 02/10/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801309
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 02/10/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801313
Principal investigator 1 Merck Sharp & Dohme Corporation $5.76 02/10/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801647
Principal investigator 1 Merck Sharp & Dohme Corporation $66.06 02/10/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801651
Principal investigator 1 Merck Sharp & Dohme Corporation $70.74 02/10/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801973
Recipient Eli Lilly and Company $1,309.80 01/28/2020 Covered Recipient Physician A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728723701
Principal investigator 1 Incyte Corporation $2,907.00 01/22/2020 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFO
Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome Myeloproliferative Neoplasm No dispute reported 06/30/2026 744283279
Principal investigator 1 Merck Sharp & Dohme Corporation $1.28 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798513
Principal investigator 1 Merck Sharp & Dohme Corporation $17.70 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798515
Principal investigator 1 Merck Sharp & Dohme Corporation $23.60 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798517
Principal investigator 1 Merck Sharp & Dohme Corporation $35.96 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798519
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798521
Principal investigator 1 Merck Sharp & Dohme Corporation $78.75 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740798523
Principal investigator 1 Merck Sharp & Dohme Corporation $0.27 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800091
Principal investigator 1 Merck Sharp & Dohme Corporation $0.60 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800093
Principal investigator 1 Merck Sharp & Dohme Corporation $0.76 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800095
Principal investigator 1 Merck Sharp & Dohme Corporation $0.92 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800261
Principal investigator 1 Merck Sharp & Dohme Corporation $1.36 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800263
Principal investigator 1 Merck Sharp & Dohme Corporation $1.48 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800265
Principal investigator 1 Merck Sharp & Dohme Corporation $1.90 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800267
Principal investigator 1 Merck Sharp & Dohme Corporation $13.60 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800269
Principal investigator 1 Merck Sharp & Dohme Corporation $17.28 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800579
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800583
Principal investigator 1 Merck Sharp & Dohme Corporation $21.36 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800591
Principal investigator 1 Merck Sharp & Dohme Corporation $21.83 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800595
Principal investigator 1 Merck Sharp & Dohme Corporation $220.20 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800599
Principal investigator 1 Merck Sharp & Dohme Corporation $235.80 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800937
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800941
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800945
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800951
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740800955
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801293
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801297
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801301
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801305
Principal investigator 1 Merck Sharp & Dohme Corporation $39.48 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801639
Principal investigator 1 Merck Sharp & Dohme Corporation $5.28 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801643
Principal investigator 1 Merck Sharp & Dohme Corporation $7.60 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801655
Principal investigator 1 Merck Sharp & Dohme Corporation $7.60 01/09/2020 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740801659
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $370.50 01/02/2020 Non-covered Recipient Entity
Providence Health System Southern Ca
PCYC-1145-LT No dispute reported 06/30/2026 727725291